Formed in February of 2016 as a spinout by Beech Tree Labs, Inc. (BTL), Resolys Bio is a privately held clinical-stage biotechnology company focusing on therapeutic agents for chronic disorders for which there is little or no competition. The lead indications of Resolys Bio are traumatic brain injury (TBI) and chronic tissue disorders such as Joint Hypermobility Syndromes (JHS), Lupus, Rheumatoid Arthritis, and Fibromyalgia.
Resolys has been assigned all rights, current and future, for formulations addressing these disorders which were developed by Beech Tree Labs, and is now engaged in formal evaluation and commercialization of these promising drug development programs.
Given the tremendous human and monetary costs imposed on society by chronic TBI (cTBI), a drug that could successfully reverse the cognition, memory, mood, and personality deficits that define this condition would represent an enormous breakthrough. Resolys Bio’s drug OSLO has demonstrated utility in diseases associated with dysfunctional collagen deposition ranging from acne and burn scars to cardiomyopathy, chronic obstructive pulmonary disease, and kidney disease, among others. While scar-like activity in the brain appears to be different from that in other parts of the body, the brain’s form of scarring also appears to be respond to OSLO therapy, which represents hope for patients with cTBI, Alzheimer’s disease, and memory loss.
The Resolys combination of repurposed biological compounds, MCC, addresses chronic, painful tissue disorders that affect about 20 percent of the U.S. population. MCC has been shown, for example, to alleviate symptoms of hypermobile Ehlers-Danlos Syndromes (hEDS) within one month. Physicians treating disorders that include chronic pain and fatigue, such as hEDS and other Joint Hypermobility Syndromes, urge the Company to focus first on this application because it is widely regarded as a condition for which there is no therapy.
© Resolys Bio, Inc.